IHCH-7086 is a non-hallucinogenic serotonin 5-HT2A receptor biased agonist of the pyridopyrroloquinoxaline family. It was derived via structural simplification of the serotonin 5-HT2A receptor antagonist and atypical antipsychotic lumateperone. The drug produces antidepressant-like effects but not psychedelic-like effects in rodents. Other related compounds include IHCH-7079, which is a non-hallucinogenic serotonin 5-HT2A receptor biased agonist similarly, and IHCH-7113, which produces the head-twitch response in rodents and hence would be expected to be hallucinogenic in humans.[1][2][3]

See also

References

  1. ↑ US 6552017, Robichaud AJ, Lee T, Deng W, Mitchell IS, Yang MG, Haydar S, Chen W, Mc Clung CD, Calvello EJ, Zawrotny DM, "Substituted heterocycle fused gamma-carbolines.", issued 22 April 2003, assigned to Bristol Myers Squibb Pharma Co.
  2. ↑ US 9315504, Tomesch JC, Li P, Yao W, Zhang Q, Beard JD, Thompson AS, Cheng H, Wennogle LP, "Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof", issued 19 April 2016, assigned to Intra Cellular Therapies Inc.
  3. ↑ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.
source: https://en.wikipedia.org/wiki/IHCH-7086